AI drug discovery company

Inceptive

Data as of Oct 17, 2026.

Company facts

Founded

2021

ReportedSource for founded (opens in new tab)
Headquarters

United States (Palo Alto, CA), with offices in Berlin and Zurich

ConfirmedSource for headquarters (opens in new tab)

Latest funding round

Round: Strategic equity (part of 30000000 Alnylam upfront)
Date: Jun 3, 2026
Amount: undisclosed
Lead investor: Alnylam (strategic equity within the collaboration)

ConfirmedSource for the latest round (opens in new tab)

Drug discovery partners

1 pharma. Pharma here means a company with approved products and roughly $1B or more in annual revenue.

Alnylam Pharma

Discovery collaboration and equity, Jun 3, 2026

$30M upfront ($2B total potential)

ConfirmedSource for Alnylam (opens in new tab)

Big tech ties

Not counted as pharma partners.

NVIDIA (NVentures)

Investor (2023 $100M round co-lead), Sep 7, 2023

ReportedSource for NVIDIA (NVentures) (opens in new tab)

Recent news

Jun 3, 2026

Alnylam's first AI drug discovery deal, valued at up to $2B per third-party post; Inceptive's earlier Sanofi deal reported no longer active

ConfirmedSource (opens in new tab)
Jun 3, 2026

Strategic equity (part of 30000000 Alnylam upfront): undisclosed

ConfirmedSource (opens in new tab)

Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.

Spot an error? Tell me and I'll fix it.